Several software tools are available that facilitate the use of the NONMEM software and
extend its functionality. This tutorial shows how three commonly used and freely available …

Abstract Background and Objectives Upadacitinib is a janus kinase (JAK) 1 inhibitor being
developed for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases …

Background Remimazolam is a new benzodiazepine for procedural sedation and general
anaesthesia. The aim of this study was to characterise its pharmacokinetic properties and …

Population pharmacokinetic models are used to describe the time course of drug exposure
in patients and to investigate sources of variability in patient exposure. They can be used to …

This article represents the first in a series of tutorials on model evaluation in nonlinear mixed
effect models (NLMEMs), from the International Society of Pharmacometrics (ISoP) Model …

This document was developed to enable greater consistency in the practice, application,
and documentation of Model‐Informed Drug Discovery and Development (MID3) across the …

Nivolumab is a fully human monoclonal antibody that inhibits programmed death‐1
activation. The clinical pharmacology profile of nivolumab was analyzed by a population …

Wide-Ranging Coverage of Parametric Modeling in Linear and Nonlinear Mixed Effects
Models Mixed Effects Models for the Population Approach: Models, Tasks, Methods and …

Population pharmacodynamic (PD) models describe the time course of drug effects, relating
exposure to response, and providing a more robust understanding of drug action than single …

ABSTRACT A previous pharmacokinetic study on dosing of colistin methanesulfonate (CMS)
at 240 mg (3 million units [MU]) every 8 h indicated that colistin has a long half-life, resulting …